WisdomTree BioRevolution UCITS ETF – USD Acc
The WisdomTree BioRevolution UCITS ETF (the “Fund”) seeks to track the price and yield performance, before fees and expenses, of the WisdomTree BioRevolution ESG Screened Index (the "Index"). Learn more about the Index that WDNA is designed to track.
- The Fund offers access through direct investment in publicly listed companies, which will be significantly transformed by advancements in genetics and biotechnology (including COVID-19 vaccines).
- Focused exposure to businesses that have multi-sector genetics and biotechnology investments with strong growth characteristics and which meet WisdomTree’s ESG (environmental, social and governance) criteria
- The research for the selection of companies in the Index and, subsequently, the Fund, is conducted by expert in the BioRevolution space, ensuring the portfolio remains focused and relevant
- The ETF is physically backed and UCITS compliant
Potential Risks
- Although the Index was created to select companies with a relatively higher exposure to BioRevolution activities, there is no guarantee this objective will be achieved.
- An investment in equities may experience high volatility and should be considered as a long-term investment.
- Higher growth companies such as those that play a part in megatrends tend to trade at higher valuations. The investor should consider the risk that comes with higher valuations as part of any investment decision.
- Investment risk may be concentrated in specific sectors, countries, companies or currencies.
- This list does not cover all risks-further risks are disclosed in the KIID and Prospectus
Overview
| Product Overview | |
|---|---|
| Asset Class | Equities |
| Use of Income | Accumulating |
| Base Currency | USD |
| Dividend Frequency | N/A |
| Inception Date | 06 Dec 2021 |
| Exchange Ticker | WDNA/WBIO |
| TER | 0.45% |
| Structure | |
|---|---|
| Replication Method | Physical, Fully Replicated |
| Legal Form | Irish Collective Asset-management Vehicle (ICAV) |
| Fund Umbrella | WisdomTree Issuer ICAV |
| Domicile | Ireland |
| Structure | Open-ended Exchange Traded Fund |
| Financial Year End | 31 December |
| UCITS Compliant | Compliant |
| Further Legal and Tax Information | |
|---|---|
| ISA | Eligible |
| SIPP | Eligible |
| UCITS Eligible | Eligible |
| UK Reporting Status | Yes |
| PEA Eligible | No |
| Key Service Providers | |
|---|---|
| Custodian | The Bank of New York Mellon SA/NV, Dublin Branch |
| Administrator | BNY Mellon Fund Services (Ireland) Designated Activity Company |
| Fund Manager | Irish Life Investment Managers |
| Auditor | Deloitte Ireland LLP |
Austria
Denmark
Finland
France
Germany
Ireland
Italy
Luxembourg
Netherlands
Norway
Spain
Sweden
United Kingdom
| Market Capitalization | As of 02 Jun 2026 |
|---|---|
| Total Market Capitalization ($ Trillion) | 4.35 |
| Fund MarketCap Breakdown | |
| Large Cap (> $10 Billion) | 50.33% |
| Mid Cap (≥ $2 Billion and ≤ $10 Billion) | 32.91% |
| Small Cap (< $2 Billion) | 16.76% |
| Fund Characteristics | As of 02 Jun 2026 |
|---|---|
| *Dividend Yield | 0.64 |
| Price/Earnings | -23.03 |
| Estimated Price/Earnings | -39.19 |
| Price/Book | 3.28 |
| Price/Sales | 3.48 |
| Price/Cash Flow | -41.27 |
| Gross Buyback Yield | 0.94 |
| Net Buyback Yield | -2.95 |
Listings & Codes
| Listings & Codes | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
||||||||||||||||||||||||
|
||||||||||||||||||||||||
|
||||||||||||||||||||||||
|
||||||||||||||||||||||||
|
||||||||||||||||||||||||
|
Holdings
Sector Breakdown
Index Details
The index is designed to track performance of companies that will be significantly transformed by advancements in genetics and biotechnology (including COVID-19 vaccines). The index excludes companies which do not meet WisdomTree’s ESG (environmental, social and governance) criteria.
To be included in the Index, companies must meet certain risk management criteria, as well as minimum liquidity requirements, WisdomTree’s ESG screen and be issued involved in BioRevolution activities. The key sectors listed below are used as guidelines to determine if a company is primarily involved in BioRevolution Activities, including Human health, Agriculture & Food, Materials, Chemicals, & Energy and Biological Machines & Interfaces.
| Index Details | |
|---|---|
| Index Name | WisdomTree BioRevolution ESG Screened Index |
| Currency | USD |
| Index Provider | WisdomTree, Inc |
| Bloomberg Ticker | WTEDNAN |
| Leverage Factor | N/A |
| Documents and Links |
|---|
Responsible Investing
SFDR Disclosure
The EU Sustainable Finance Disclosures Regulation (SFDR) took effect on 10 March 2021 as part of the EU Action Plan on Sustainable Finance. The SFDR lays down harmonised sustainability related disclosure rules for EU financial market participants and advisors and requires certain sustainability disclosures to be made for financial products which promote environmental or social characteristics (Article 8 SFDR) and funds which have a sustainable investment objective (Article 9 SFDR).
There are different SFDR product categorisations for these sustainability disclosure requirements:
+ Article 6 products: require disclosures relating to the manner in which sustainability risks are integrated into the decision-making process.
+ Article 8 products: promote, among other characteristics, environmental or social characteristics or a combination of those characteristics, provided that the companies in which the investments are made follow good governance practices.
+ Article 9 products: have sustainable investment as their objective
Please refer to EU regulation guidelines for more details: https://www.esma.europa.eu/sections/sustainable-finance
| SFDR categorisations | |
|---|---|
| SFDR Disclosure | Article 8 |
ESG Characteristics
The fund tracks an index which seeks to exclude from the eligible investment universe companies that (i) violate, certain commonly accepted international norms and standards, such as United Nations and the Organisation for Economic Co-operation and Development (OECD) guidelines, ((ii) are involved in certain controversial weapons such as anti-personnel mines and cluster munitions as well as those involved in depleted uranium weapons and white phosphorus weapons and those that support nuclear weapons programmes to states outside the Treaty on the Non-Proliferation of Nuclear Weapons (commonly known as the Non-Proliferation Treaty or “NPT”), (iii) are significantly involved in the tobacco industry, (iv) are significantly involved in thermal coal activity, such as coal mining and exploration and coal-based power generation, (v) are significantly involved in unconventional oil and gas exploration/production, such as oil sands, Arctic oil and gas or shale energy, (vi) do not meet such other ESG criteria such as significant involvement in small arms, as detailed in the Index methodology. Visit our ESG Hub to learn more about WisdomTree's ESG approach.
MSCI ESG Research LLC’s (“MSCI ESG”) Fund Metrics and Ratings (the “Information”) provide environmental, social and governance data with respect to underlying securities within more than 31,000 multi-asset class Mutual Funds and ETFs globally. MSCI ESG is a Registered Investment Adviser under the Investment Advisers Act of 1940. MSCI ESG materials have not been submitted to, nor received approval from, the US SEC or any other regulatory body. None of the Information constitutes an offer to buy or sell, or a promotion or recommendation of, any security, financial instrument or product or trading strategy, nor should it be taken as an indication or guarantee of any future performance, analysis, forecast or prediction. None of the Information can be used to determine which securities to buy or sell or when to buy or sell them. The Information is provided “as is” and the user of the Information assumes the entire risk of any use it may make or permit to be made of the Information.
| Sustainability Characteristics | |
|---|---|
| MSCI ESG Fund Ratings (AAA-CCC) | A |
Documents
DISCLAIMERS
The products discussed in this document are issued by WisdomTree Issuer ICAV (“WT Issuer”). WT Issuer is an umbrella investment company with variable capital having segregated liability between its funds organised under the laws of Ireland as an Irish Collective Asset-management Vehicle and authorised by the Central Bank of Ireland (“CBI”). WT Issuer is organised as an Undertaking for Collective Investment in Transferable Securities (“UCITS”) under the laws of Ireland and shall issue a separate class of shares ("Shares”) representing each fund.
The Fund is described in a Key Information Document (KID) or Key Investor Information Document (KIID) for UK investors, and the prospectus of WT Issuer (“WT Prospectus”). A copy of the WT Prospectus and the KID / KIID is available, for EEA/UK only, in English at www.wisdomtree.eu. Where required under national rules, the KID will also be available in the local language of the relevant EEA Member State. Investors should read the WT Prospectus before investing and should refer to the section of the WT Prospectus entitled ‘Risk Factors’ for further details of risks associated with an investment in the Shares.
The summary of investor rights associated with an investment in the fund is available in English on WisdomTree Europe’s website. WisdomTree Management Limited may decide to terminate the arrangements made for the marketing of its collective investment undertakings. In such circumstances, shareholders in the affected EEA Member State will be notified of this decision and will be provided with the opportunity to redeem their shareholding in the fund free of any charges or deductions for at least 30 working days from the date of such notification.
This product is based overseas and is not subject to UK sustainable investment labelling and disclosure requirements. Please refer to the FCA website which details further information in relation to sustainability disclosure requirements.